[Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes]

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Nephrology

Background:

• Diabetic vascular complications, including blindness and renal failure, are major causes of morbidity and mortality.
• Accelerated formation of advanced glycation end products (AGEs) is a hallmark of diabetes.
• The receptor for AGEs (RAGE) system plays a critical role in the pathogenesis of diabetic vascular complications.

Purpose of the Study:

• To explore the AGE-RAGE axis as a therapeutic target for diabetic vascular complications.
• To investigate the potential of nifedipine, a calcium channel blocker, in mitigating AGE-RAGE related pathways.

Main Methods:

• Review of current understanding of AGEs, RAGE, and their role in diabetic vascular disease.
• Analysis of recent findings on nifedipine's properties, including its antioxidant and anti-AGE-RAGE axis effects.

Main Results:

• The AGE-RAGE system is significantly implicated in the development of diabetic vascular complications.
• Nifedipine exhibits antioxidant and anti-AGE-RAGE axis properties.
• Nifedipine may offer additional benefits beyond blood pressure control in preventing cardiorenal events in diabetics.

Conclusions:

• Inhibition of the AGE-RAGE axis presents a promising therapeutic strategy for diabetic vascular complications.
• Nifedipine's demonstrated effects on the AGE-RAGE axis suggest its potential utility in managing diabetic vascular disease.
• Combining blood glucose/pressure control with AGE-RAGE axis inhibition, possibly via nifedipine, could improve outcomes for diabetic patients.